ReachMD

Be part of the knowledge.™

Pathology and Laboratory Medicine

511

LikeLikedUnlike

Episodes 31-45 of 67

Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
MinuteCE®
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
- Erica L. Mayer, MD, MPH
  Peer
1.00 program credits
MinuteCE®
Expanding ADCs Across Metastatic Breast Cancer: Disrupting Dx & Tx Silos
- Erica L. Mayer, MD, MPH
  Peer
- Sarah Sammons, MD
  Peer
1.00 credits 9 episodes
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
MinuteCE®
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
- Sarah Sammons, MD
  Peer
1.00 program credits
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
MinuteCE®
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
- Erica L. Mayer, MD, MPH
  Peer
1.00 program credits
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
MinuteCE®
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
- Sarah Sammons, MD
  Peer
1.00 program credits
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
MinuteCE®
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
- Erica L. Mayer, MD, MPH
  Peer
- Sarah Sammons, MD
  Peer
1.00 program credits
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
MinuteCE®
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
- Sarah Sammons, MD
  Peer
1.00 program credits
Late-Stage Bispecifics and ADCs in DLBCL
MinuteCE®
Late-Stage Bispecifics and ADCs in DLBCL
- Sarah Rutherford, MD
  Peer
- John P. Leonard, MD
  Peer
1.00 program credits
Antibody-Drug Conjugates in FL
MinuteCE®
Antibody-Drug Conjugates in FL
- Matthew J. Matasar, MD
  Peer
- Kami Maddocks, MD
  Peer
1.00 program credits
Application of Data from the ECHELON-1 Trial
MinuteCE®
Application of Data from the ECHELON-1 Trial
- Alison J. Moskowitz, MD
  Peer
- Alex Herrera, MD
  Peer
1.00 program credits
NCCN Guideline Updates in DLBCL
MinuteCE®
NCCN Guideline Updates in DLBCL
- John P. Leonard, MD
  Peer
- Sarah Rutherford, MD
  Peer
1.00 program credits
MinuteCE®
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
- John P. Leonard, MD
  Peer
- Matthew J. Matasar, MD
  Peer
- Alex Herrera, MD
  Peer
- Kami Maddocks, MD
  Peer
- Alison J. Moskowitz, MD
  Peer
- Sarah Rutherford, MD
  Peer
1.00 credits 9 episodes
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
MinuteCE®
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
- Alex Herrera, MD
  Peer
- Alison J. Moskowitz, MD
  Peer
1.00 program credits
Individualizing Frontline Treatment
MinuteCE®
Individualizing Frontline Treatment
- Alex Herrera, MD
  Peer
- Alison J. Moskowitz, MD
  Peer
1.00 program credits
Patient Selection for ADCs in First-Line DLBCL
MinuteCE®
Patient Selection for ADCs in First-Line DLBCL
- John P. Leonard, MD
  Peer
- Sarah Rutherford, MD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended